<DOC>
	<DOCNO>NCT01959633</DOCNO>
	<brief_summary>The hypothesis study evaluate safety efficacy Vemurafenib/PEG-interferon combination IFNAR1 upregulation lead treatment .</brief_summary>
	<brief_title>Study Combination Vemurafenib Plus PEG-interferon Advanced Melanoma Patients Harboring V600BRAF Mutation</brief_title>
	<detailed_description>Phase I include 9 patient common design 3+3+3 . This phase last MTD reach patient part cohort select due MTD extend phase II . In phase II , 42 patient enrol . Vemurafenib 960 mg b.i.d . + Peg-interferon 1/2/3 micrograms/Kg one time per week ( MTD reach ) Interferon treatment start 15 day Vemurafenib . In Phase I group 3 patient enter dose level ( vemurafenib 960 mg b.i.d . + Peg-interferon 1/2/3 micrograms/Kg ) . If 3 patient treat dose level observe 2 course therapy without DLT , dose escalate . If least 2/3 patient DLT , previous dose level consider MTD . If 1/3 patient DLT , 3 patient treat dose level . If none patient DLT , dose escalate . If least one 3 additional patient DLT , previous dose consider MTD . This phase II aim : - verify combination Vemurafenib plus PEG-interferon advance melanoma patient harbor V600BRAF mutation active standard therapy ( Vemurafenib ) report literature . Therefore , low response probability interest 32 week set .40 , combination treatment develop response time least .60 . - verify upregulation IFNAR1 expression patient treat combination Vemurafenib plus PEG-interferon Therefore , low expression probability interest 7 day set .10 , combination treatment develop expression least .90 . Taking account 10 % drop-out rate , total 48 patient enrolled ensure minimum 42 evaluable patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>1 . Patients 18 2 . Untreated pretreated ( 1 treatment ) patient metastatic melanoma stage unreseactable IIIbIV , histologically confirm , show V600 type BRAF mutation . Patients eligible Phase I may pretreated investigational study treatment . 3 . Patient measurable disease RECIST v 1.1 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 5 . Patients successfully complete secondary side effect previous systemic therapy 6 . Patients appropriate hematologic , hepatic renal functionality , assess 7 day precede start therapy , well : Absolute neutrophil count ( ANC ) &gt; 1.5 X 109 / L Absolute platelet count &gt; 100 X 109 / L Hemoglobin &gt; 9 g/dl Serum creatinine &lt; 1.5 time normal maximum value Creatinine Clearance &gt; 50 mL/hr ( CockroftGault formula ) Transaminase level ( AST ALT ) &lt; 2.5 time normal maximum value Serum bilirubin &lt; 1.5 time normal maximum value 7 . Negative pregnancy test perform within 7 day begin therapy ( premenopausal woman ) 8 . Patients childbearing age ( partner childbearing age ) must use effective contraception therapy least 6 month effective treatment 9 . Absence psychological , familiar social condition may affect compliance study protocol schedule followup 10 . Dated sign informed consent study procedure 1 . Presence symptomatic brain metastasis 2 . Previous malignant cancer 2 year precede signing inform consent 3 . Investigational study treatment within 28 day 5 halflives , whichever longer , precede first dose study treatment study 4 . Pregnancy and/or breast feeding ; 5 . Nausea vomit refractory therapy , malabsorption , external biliary shunt , previous bowel resection , could impair adequate absorption 6 . Any condition occur 6 month start Vemurafenib therapy : heart attack , unstable angina and/or severe degree , congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , arterial hypertension adequately control 7 . History atrial ventricular arrhythmia , symptomatic &gt; grade 2 ( NCI CTCAE ) 8 . Hystory retinopathy 9 . Correct QT interval &gt; 450msec baseline history congenital long QT syndrome 10 . Uncontrolled medical condition among endocrine disorder ( hypothyroidism , hyperthyroidism diabetes mellitus ) 11 . Other severe medical psychiatric condition abnormality laboratory test may increase risk associate study participation assumption Vemurafenib , may interfere interpretation study result , judgment Investigator make patient eligible study 12 . Unwillingness practice adequate contraception 13 . Prior systemic treatment BRAFi MEKi , interferon alpha</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>